Single-layer placental graft plus standard care for stubborn diabetic foot ulcers

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

This trial will try a single-layer placental-based graft together with usual wound care for adults whose diabetic foot ulcers did not heal after standard treatment in an earlier trial.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Applied Biologics, LLC (Industry-sponsored)
• Drugs / interventions: chemotherapy, prednisone
• Locations: 1 site (Hollywood, Florida)
• Trial ID: NCT07159282 on ClinicalTrials.gov

What this trial studies

This is a multicenter, prospective, controlled Phase 4 rescue trial that gives a single-layer placental-based allograft in addition to standard of care to patients who failed to achieve closure in the standard-of-care arm of the prior CAMPX trial. Participants must meet local Medicare LCD medical necessity criteria for cellular/acellular matrix-like products and agree to weekly clinic visits and prescribed offloading. The protocol requires consent, target ulcer confirmation (diabetes-related), and excludes infected ulcers and patients with life expectancy under six months. The trial is managed by Applied Biologics with sites including Royal Research in Hollywood, Florida.

Who should consider this trial

Good fit: Adults (18+) with a diabetes-related foot ulcer who were in the CAMPX trial SOC arm and did not achieve complete closure by 12 weeks, meet local Medicare criteria for CAMPs, and can attend weekly visits and use prescribed offloading are ideal candidates.

Not a fit: Patients with non-diabetic ulcers, infected ulcers or cellulitis at the target site, those with life expectancy under six months, or those who already healed or who do not meet Medicare LCD criteria are unlikely to benefit from this rescue intervention.

Why it matters

Potential benefit: If successful, the treatment could increase healing rates for nonhealing diabetic foot ulcers and reduce the need for further invasive procedures.

How similar studies have performed: Related placental- and amniotic-derived graft products have shown improved healing in prior trials, but product-specific and rescue-design data remain limited.

Eligibility criteria

Inclusion Criteria:

* The potential subject must be at least 18 years of age or older.
* The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
* If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the CAMPX study.
* The potential subject must consent to using the prescribed offloading method for the duration of the study.
* The potential subject must agree to attend the weekly study visits required by the protocol.
* The potential subject must be willing and able to participate in the informed consent process.
* The potential subject must have participated in the CAMPX trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint.

Exclusion Criteria:

* The potential subject is known to have a life expectancy of \< 6 months.
* The potential subject's target ulcer is not secondary to diabetes.
* The target ulcer is infected or there is cellulitis in the surrounding skin.
* The target ulcer exposes tendon or bone.
* There is evidence of osteomyelitis complicating the target ulcer.
* There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
* The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
* The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
* The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
* The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
* The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
* The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
* The potential subject has end stage renal disease requiring dialysis.
* The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
* The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.
* The potential subject did not participate in the CAMPX trial.
* The potential subject participated in the CAMPX trial and was not randomized to the SOC only arm.
* The potential subject participated in the CAMPX trial and achieved complete closure.

Where this trial is running

Hollywood, Florida

• Royal Research — Hollywood, Florida, United States (Recruiting)

Study contacts

• Study coordinator: Bennett Sarver

Conditions Diabetic Foot; Foot Ulcer; Ulcer Foot; DFU; Foot Ulcer Due to Type 2 Diabetes Mellitus; Foot Ulcer Due to Type 1 Diabetes Mellitus; Diabetic Foot Ulcer